A Study of GR1803 in Systemic Lupus Erythematosus
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorGenrix (Shanghai) Biopharmaceutical Co., Ltd.
About this trial
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Eligibility criteria
Qualifiers
comfirmed diagnosis of systemic lupus erythematosus
SLEDAI-2K≥6分
written informed consent and ability to comply with protocol requirements
have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months
Disqualifiers
with unstable acute and chronic diseases
active infection
history of malignant tumor within 5 years
Trial design
Treatments tested in this trial
- GR1803 injection
Treatment groups
44 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov